WASHINGTON — A few weeks after the Bush administration named Medco to be one of the first Medicare drug card providers, a company executive helped throw a $100,000 fund-raiser for the president that was headlined by Health and Human Services Secretary Tommy Thompson.
The role of Medco Specialty Pharmacy Services President Alan Lotvin, a co-chairman of the mid-April event in New Jersey, is just one of the ways prescription drug card providers have reached out to Washington politicians over the last two years.
In all, companies that won approval from Thompson's department to be the first Medicare drug discount card providers spent at least $35 million lobbying in 2003, and their executives and lobbyists donated or raised hundreds of thousands of dollars more for Bush's re-election, an Associated Press review found.
Democratic rival John Kerry received a much smaller amount from the same group.
While spokesmen for Thompson and Lotvin say the fund-raiser wasn't connected to the drug cards, a longtime Washington lobbyist says it provides a textbook example of how big companies sow goodwill and win access when business is pending before the government.
"I think it is generally recognized in Washington that involvement in the campaign finance process certainly often can be very helpful to your legislative agenda," said Wright Andrews, a former president of the American League of Lobbyists. "It does tend to provide you better access in that people logically are likely to at least ensure that they hear you out."
Lotvin's parent company, pharmaceutical-benefit manager Medco Health Solutions, and its then-owner, pharmaceutical giant Merck, together spent about $8 million on lobbying in the capital last year. Merck spun off Medco as a separate company late last summer.
"We think the Medicare discount card is good public policy and it's going to help a lot of people," Medco spokeswoman Jennifer Leone said. "We think we were chosen because we can offer a significant benefit to Medicare beneficiaries who need help paying for their prescription drugs."
Leone said Lotvin took part in the Bush fund-raiser as a private citizen and has little to do with Medco's Medicare drug card services.
HHS spokesman Bill Pierce said Thompson had "no role whatsoever" with his department's selection of Medicare drug card providers. The companies had to go through "a very long and involved process" to be certified by the department's Centers for Medicare & Medicaid Services, he said.
Dozens of companies have won HHS approval since mid-March to offer Medicare drug discount cards. Consumers began signing up for the cards last week and can begin using them in June.
Some companies can offer the cards nationwide, others only to their own plan members. Even the ability to provide them on a limited basis is potentially lucrative, attracting a client base the companies hope to keep when Medicare prescription drug coverage begins in 2006.
A handful of the winning companies make up the lion's share of the political spending.
In addition to Merck and Medco, others with seven-figure lobbying expenses in 2003 included Blue Cross & Blue Shield Association (at least $8.1 million), Aetna (at least $2.9 million), Wellpoint Health Networks (at least $1.5 million), Pacificare ($1.42 million), and United Healthcare ($1.2 million).